Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – October 19, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Company” or “Innocan“), is pleased to announce the results of a recent study showed the presence of Cannabidiol (CBD) in mice’s brains, 41 days after being injected with Innocan’s CBD LPT (CBD-Loaded Liposome Platform Technology). In contrast, no CBD was demonstrated in mice’s brains, 22 days following the injection of free CBD (without using Innocan’s LPT delivery system).
Figure 1. Mean brain CBD concentrations, following CBD LPT (CBD-Loaded Liposome Platform Technology) injection post 41 days vs free CBD (without using Innocan’s LPT delivery system) 22 days post injection
To view an enhanced version of this graphic, please visit:
Prolonged and controlled release of CBD from Innocan’s novel Delivery System injected subcutaneously, showed continuous clinically relevant concentrations of CBD in the blood for a long time. The Company believes this will be a good predictor of CBD exposure when administered in humans.
The Company believes that the continuous and long blood presence of CBD in blood for a longer time post local administration, seems to be superior to orally administered CBD in two aspects: (a) it will all allow a single administration of CBD instead of daily administration; and (b) it will overcome the low (10-20%) oral bioavailability of CBD. The superior PK of the CBD Delivery System administered, may achieve controlled concentration of CBD in the blood leading to a better clinical outcome.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/100173
Powered by WPeMatico